Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept …
… A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter A. Beal joins … of RNA-based therapeutics, particularly in the area of RNAediting. As an expert in the field of ADAR and A-to-I …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNAEditing Summit During the 1 st RNAEditing Summit to be held …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … advisory board. "Dr. Yu is a pioneer of targeted RNAediting to correct protein translation defects caused by …